Literature DB >> 25704270

New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

Joyce M van Dodewaard-de Jong1, Henk M W Verheul1, Haiko J Bloemendal2, John M H de Klerk3, Michael A Carducci4, Alfons J M van den Eertwegh5.   

Abstract

Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Hormonal therapy; Immunotherapy; Prostate cancer; Radiopharmaceuticals

Mesh：

Substances：

Year:  2015        PMID： 25704270     DOI： 10.1016/j.clgc.2015.01.008

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


  14 in total

1.  A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.

Authors:  Joyce M van Dodewaard-de Jong; John M H de Klerk; Haiko J Bloemendal; Daniela E Oprea-Lager; Otto S Hoekstra; H Pieter van den Berg; Maartje Los; Aart Beeker; Marianne A Jonker; Joe M O'Sullivan; Henk M W Verheul; Alfons J M van den Eertwegh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-18       Impact factor: 9.236

2.  Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.

Authors:  Claire M Faltermeier; Justin M Drake; Peter M Clark; Bryan A Smith; Yang Zong; Carmen Volpe; Colleen Mathis; Colm Morrissey; Brandon Castor; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

3.  Metastatic Prostate Cancer to the Left Temporal Bone: A Case Report and Review of the Literature.

Authors:  Erynne A Faucett; Hal Richins; Rihan Khan; Abraham Jacob
Journal:  Case Rep Otolaryngol       Date:  2015-07-30

4.  The pepper's natural ingredient capsaicin induces autophagy blockage in prostate cancer cells.

Authors:  Ágata Ramos-Torres; Alicia Bort; Cecilia Morell; Nieves Rodríguez-Henche; Inés Díaz-Laviada
Journal:  Oncotarget       Date:  2016-01-12

Review 5.  Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions.

Authors:  Mohamed Ben-Eltriki; Subrata Deb; Emma S Tomlinson Guns
Journal:  J Cancer       Date:  2016-01-15       Impact factor: 4.207

6.  Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.

Authors:  Shumin Zhang; Lajos Gera; Kenza Mamouni; Xin Li; Zhengjia Chen; Omer Kucuk; Daqing Wu
Journal:  Oncotarget       Date:  2016-05-10

7.  Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.

Authors:  Romana Mikyšková; Ivan Štěpánek; Marie Indrová; Jana Bieblová; Jana Šímová; Iva Truxová; Irena Moserová; Jitka Fučíková; Jiřina Bartůňková; Radek Špíšek; Milan Reiniš
Journal:  Int J Oncol       Date:  2015-12-29       Impact factor: 5.650

8.  First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel.

Authors:  Jian-Ri Li; Shian-Shiang Wang; Cheng-Kuang Yang; Chuan-Su Chen; Hao-Chung Ho; Kun-Yuan Chiu; Chi-Feng Hung; Chen-Li Cheng; Chi-Rei Yang; Cheng-Che Chen; Shu-Chi Wang; Chia-Yen Lin; Yen-Chuan Ou
Journal:  Front Pharmacol       Date:  2017-02-13       Impact factor: 5.810

9.  Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.

Authors:  Filipe Pinto; Nelma Pértega-Gomes; José R Vizcaíno; Raquel P Andrade; Flavio M Cárcano; Rui Manuel Reis
Journal:  Oncotarget       Date:  2016-05-17

10.  Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.

Authors:  Giacomo Canesin; Susan Evans-Axelsson; Rebecka Hellsten; Agnieszka Krzyzanowska; Chandra P Prasad; Anders Bjartell; Tommy Andersson
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.